ALK and neoplasm: Tumor cell line derived from this patient was inhibited by 1 μM crizotinib (p < 0.0001, one-way ANOVA test) or to a greater extent with 1 μM entrectinib (p < 0.0001 vs. no ALK inhibitor; p < 0.0001 vs. crizotinib one-way ANOVA test) (Figure 3D).